Rheumatology Department, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, 78 Avenue du general Leclerc, 94270, Le Kremlin-Bicêtre, France.
Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, Le Kremlin-Bicêtre, France.
J Hematol Oncol. 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2.
Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple myeloma (MM) patients (n = 27). Response was analyzed 1 month after the second dose of anti-SARS-CoV-2 BNT162b2 vaccine. Multiple myeloma patients showed diminished levels of Anti-Spike IgG levels compared to controls, but with a high proportion of patients achieving a humoral response (89% vs. 97% in controls). Neutralizing antibodies were present in 74% of patients versus 96% of controls. Patients under current daratumumab treatment had neutralizing activity of anti-SARS-CoV-2 antibodies. Multiple myeloma patients show diminished response to SARS-COV-2 vaccine but with still high response rate. The main potential risk factor of non-response to COVID-19 vaccine was uncontrolled disease under treatment.
多发性骨髓瘤患者患严重 COVID-19 的风险较高。尽管有数据显示疫苗反应减弱，但高效的 mRNA 疫苗时代可能会改变游戏规则。我们试图检查健康对照组（n=28）和多发性骨髓瘤（MM）患者（n=27）对 mRNA 疫苗的反应。在接种第二剂抗 SARS-CoV-2 BNT162b2 疫苗后 1 个月分析反应。与对照组相比，多发性骨髓瘤患者的 Anti-Spike IgG 水平降低，但仍有很高比例的患者产生体液反应（对照组为 89%，MM 患者为 89%）。中和抗体存在于 74%的患者中，而对照组为 96%。正在接受达雷妥尤单抗治疗的患者具有抗 SARS-CoV-2 抗体的中和活性。多发性骨髓瘤患者对 SARS-COV-2 疫苗的反应减弱，但仍有很高的反应率。对 COVID-19 疫苗无反应的主要潜在危险因素是治疗中未控制的疾病。
